Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA; Lindner Center of HOPE, Mason, OH, USA.
Eur Eat Disord Rev. 2014 Mar;22(2):140-6. doi: 10.1002/erv.2277. Epub 2014 Jan 8.
The aim of this study was to gain further understanding of placebo response in binge eating disorder.
We pooled participant-level data from 10 double-blind, placebo-controlled, randomized trials of medications for binge eating disorder. The primary outcomes were response (75% reduction in binge eating episodes), cessation of binge eating episodes, change in mean weekly binge eating episodes and binge eating episodes per week.
Of 234 participants receiving placebo, 89 (38%) were responders and 59 (26%) attained cessation. Placebo-treated participants significantly reduced their binge eating. The mean (SD) binge eating episodes per week at baseline was 5.2 (3.2) and at endpoint was 2.2 (2.6). Lower baseline binge eating episode frequency and longer study participation were significantly associated with response and cessation.
Less severe eating pathology at baseline was associated with higher placebo response and cessation rates. Future clinical trials may want to stipulate that participants exceed a threshold of illness severity, which may lead to better placebo and drug separation.
本研究旨在进一步了解暴食障碍中的安慰剂反应。
我们汇集了 10 项双盲、安慰剂对照、随机治疗暴食障碍药物的临床试验的参与者水平数据。主要结局指标是反应（暴食发作减少 75%）、停止暴食发作、每周平均暴食发作次数和每周暴食发作次数的变化。
在 234 名接受安慰剂的参与者中，89 名（38%）是应答者，59 名（26%）达到停止。接受安慰剂治疗的参与者显著减少了暴食发作。基线时每周暴食发作次数的平均值（SD）为 5.2（3.2），终点时为 2.2（2.6）。基线时暴食发作频率较低和研究参与时间较长与反应和停止显著相关。
基线时较轻的进食障碍与更高的安慰剂反应和停止率相关。未来的临床试验可能希望规定参与者超过疾病严重程度的阈值，这可能导致更好的安慰剂和药物分离。
